دورية أكاديمية
أعرض في EDS

Effect of chronic low-dose treatment with chitooligosaccharides on microbial dysbiosis and inflammation associated chronic ulcerative colitis in Balb/c mice.

التفاصيل البيبلوغرافية
العنوان: Effect of chronic low-dose treatment with chitooligosaccharides on microbial dysbiosis and inflammation associated chronic ulcerative colitis in Balb/c mice.
المؤلفون: Rajesh KM; Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India., Kinra M; Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India., Ranadive N; Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India., Pawaskar GM; Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India., Mudgal J; Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India. jayesh.mudgal@manipal.edu., Raval R; Department of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India. ritu.raval@manipal.edu.
المصدر: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2024 Mar; Vol. 397 (3), pp. 1611-1622. Date of Electronic Publication: 2023 Sep 11.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin, New York, Springer Verlag.
مواضيع طبية MeSH: Colitis, Ulcerative*/chemically induced , Colitis*/chemically induced , Colitis*/drug therapy , Colitis*/pathology , Oligosaccharides* , Chitosan*, Animals ; Mice ; Colon ; Mesalamine/pharmacology ; Mice, Inbred BALB C ; Dysbiosis/drug therapy ; Dysbiosis/metabolism ; Dysbiosis/pathology ; Inflammation/pathology ; Cytokines/metabolism ; Disease Models, Animal ; Mice, Inbred C57BL ; Dextran Sulfate/adverse effects ; Dextran Sulfate/metabolism
مستخلص: The study aimed to investigate the potential of low dose chitooligosaccharide (COS) in ameliorating dextran sodium sulfate (DSS) induced chronic colitis by regulating microbial dysbiosis and pro-inflammatory responses. Chronic colitis was induced in BALB/c mice by DSS (4% w/v, 3 cycles of 5 days) administration. The mice were divided into four groups: vehicle, DSS, DSS + mesalamine and DSS+COS. COS and mesalamine were administered orally, daily once, from day 1 to day 30 at a dose of 20 mg/kg and 50 mg/kg respectively. The disease activity index (DAI), colon length, histopathological score, microbial composition, and pro-inflammatory cytokine expression were evaluated. COS (20 mg/kg, COS Low ) administration reduced the disease activity index, and colon shortening, caused by DSS significantly. Furthermore, COS Low restored the altered microbiome in the gut and inhibited the elevated pro-inflammatory cytokines (IL-1 and IL-6) in the colon against DSS-induced chronic colitis in mice. Moreover, COS Low treatment improved the probiotic microflora thereby restoring the gut homeostasis. In conclusion, this is the first study where microbial dysbiosis and pro-inflammatory responses were modulated by chronic COS Low treatment against DSS-induced chronic colitis in Balb/c mice. Therefore, COS supplementation at a relatively low dose could be efficacious for chronic inflammatory bowel disease.
(© 2023. The Author(s).)
References: Front Immunol. 2020 Sep 15;11:2058. (PMID: 33042117)
Curr Protoc Immunol. 2014 Feb 04;104:15.25.1-15.25.14. (PMID: 24510619)
Gut Microbes. 2019;10(4):504-520. (PMID: 30663928)
Front Microbiol. 2016 Jun 09;7:868. (PMID: 27375589)
Dig Dis Sci. 2012 Feb;57(2):345-54. (PMID: 21881971)
ILAR J. 2015;56(2):192-204. (PMID: 26323629)
Dig Liver Dis. 2018 May;50(5):421-428. (PMID: 29567414)
PLoS One. 2022 Mar 9;17(3):e0264400. (PMID: 35263357)
Carbohydr Polym. 2021 Jan 15;252:117206. (PMID: 33183640)
Carbohydr Polym. 2020 Aug 15;242:116413. (PMID: 32564858)
Clin Exp Immunol. 1998 Dec;114(3):385-91. (PMID: 9844047)
Inflamm Bowel Dis. 2007 Aug;13(8):1016-23. (PMID: 17476678)
Neurosci Lett. 2002 Mar 15;321(1-2):105-9. (PMID: 11872267)
Clin Rev Allergy Immunol. 2005 Jun;28(3):187-96. (PMID: 16129903)
Mediators Inflamm. 2020 Sep 9;2020:1430605. (PMID: 32963490)
Inflamm Bowel Dis. 2014 Feb;20(2):389-97. (PMID: 24356385)
Can J Gastroenterol Hepatol. 2015 Mar;29(2):77-84. (PMID: 25803017)
Front Immunol. 2017 Aug 14;8:942. (PMID: 28855901)
Microorganisms. 2020 Nov 01;8(11):. (PMID: 33139627)
Dig Dis. 2023;41(4):656-665. (PMID: 36858036)
Microbiologyopen. 2018 Oct;7(5):e00677. (PMID: 29911322)
Sci Rep. 2020 Oct 26;10(1):18270. (PMID: 33106549)
Int J Mol Sci. 2018 Sep 18;19(9):. (PMID: 30231491)
Carbohydr Polym. 2015 Jan 22;115:448-56. (PMID: 25439918)
J Allergy Clin Immunol. 2020 Jan;145(1):16-27. (PMID: 31910984)
Mar Drugs. 2021 Mar 30;19(4):. (PMID: 33808253)
Lab Anim. 2018 Jun;52(3):240-252. (PMID: 29192559)
Int J Biol Macromol. 2022 Mar 31;202:375-387. (PMID: 35063480)
Cells. 2020 Oct 13;9(10):. (PMID: 33066233)
Front Immunol. 2018 Nov 05;9:2566. (PMID: 30455704)
J Clin Med. 2021 Apr 17;10(8):. (PMID: 33920646)
Int J Mol Sci. 2020 May 31;21(11):. (PMID: 32486445)
Clin Microbiol Rev. 2002 Jan;15(1):79-94. (PMID: 11781268)
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. (PMID: 31648971)
Front Microbiol. 2018 Mar 02;9:300. (PMID: 29551996)
Pharmacol Res. 2012 Jul;66(1):66-79. (PMID: 22475725)
Free Radic Biol Med. 1990;9(6):515-40. (PMID: 2079232)
J Exp Med. 2012 Aug 27;209(9):1595-609. (PMID: 22891275)
mSphere. 2018 Nov 14;3(6):. (PMID: 30429227)
معلومات مُعتمدة: 200900123 Manipal Academy for Higher Education
فهرسة مساهمة: Keywords: BALB/c mice; Chitooligosaccharides; DSS colitis; Gut microbiota; Inflammation; Inflammatory bowel disease (IBD)
المشرفين على المادة: 4Q81I59GXC (Mesalamine)
0 (oligochitosan)
0 (Cytokines)
9042-14-2 (Dextran Sulfate)
0 (Oligosaccharides)
9012-76-4 (Chitosan)
تواريخ الأحداث: Date Created: 20230911 Date Completed: 20240214 Latest Revision: 20240215
رمز التحديث: 20240215
مُعرف محوري في PubMed: PMC10858833
DOI: 10.1007/s00210-023-02710-3
PMID: 37695333
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1912
DOI:10.1007/s00210-023-02710-3